Regenxbio sees more enrollment in trials, shows $15M loss

Regenxbio Inc., a Rockville biotechnology company focused on gene therapy, said it was continuing to advance its product candidates and increased its cash on hand as it showed a quarterly loss. The company lost $14.5 million, or 47 cents per share, in its second quarter, which it ended with $208.5 million in cash, equivalents and …

from http://thedailyrecord.com/2017/08/09/regenxbio-sees-more-enrollment-in-trials-shows-15m-loss/

Advertisements

Author: Baltimore Checkbook

Best in consumer news and deals in Baltimore, MD.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s